Compass Therapeutics, Inc. (NASDAQ:CMPX) Insider Jonathan Anderman Acquires 20,000 Shares

Compass Therapeutics, Inc. (NASDAQ:CMPX) insider Jonathan Anderman acquired 20,000 shares of the stock in a transaction that occurred on Monday, April 7th. The stock was purchased at an average price of $1.54 per share, with a total value of $30,800.00. Following the transaction, the insider now owns 21,000 shares in the company, valued at $32,340. This represents a 2,000.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Compass Therapeutics Price Performance

Compass Therapeutics stock opened at $1.59 on Wednesday. The company has a market cap of $219.87 million, a price-to-earnings ratio of -4.30 and a beta of 1.40. The firm has a 50-day moving average of $2.67 and a 200-day moving average of $2.10. Compass Therapeutics, Inc. has a one year low of $0.77 and a one year high of $4.08.

Compass Therapeutics (NASDAQ:CMPX) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). As a group, sell-side analysts expect that Compass Therapeutics, Inc. will post -0.36 earnings per share for the current year.

Hedge Funds Weigh In On Compass Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. Intech Investment Management LLC acquired a new stake in Compass Therapeutics in the third quarter valued at $30,000. The Manufacturers Life Insurance Company bought a new position in Compass Therapeutics during the third quarter worth about $79,000. XTX Topco Ltd bought a new position in Compass Therapeutics during the third quarter worth about $37,000. Barclays PLC raised its stake in Compass Therapeutics by 195.4% in the third quarter. Barclays PLC now owns 170,245 shares of the company’s stock valued at $314,000 after buying an additional 112,614 shares during the period. Finally, Geode Capital Management LLC lifted its position in shares of Compass Therapeutics by 0.8% in the third quarter. Geode Capital Management LLC now owns 2,309,778 shares of the company’s stock valued at $4,251,000 after buying an additional 19,095 shares during the last quarter. 68.43% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on CMPX. Leerink Partnrs raised Compass Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, April 1st. Guggenheim reaffirmed a “buy” rating and issued a $12.00 price target on shares of Compass Therapeutics in a research note on Wednesday, April 2nd. HC Wainwright increased their price objective on shares of Compass Therapeutics from $10.00 to $24.00 and gave the stock a “buy” rating in a research report on Friday, April 4th. D. Boral Capital reaffirmed a “buy” rating and issued a $32.00 price objective on shares of Compass Therapeutics in a research report on Tuesday, April 1st. Finally, Wedbush reiterated an “outperform” rating and set a $8.00 target price on shares of Compass Therapeutics in a report on Tuesday, April 1st. Eight analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Compass Therapeutics has a consensus rating of “Buy” and an average price target of $13.38.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.